Last reviewed · How we verify
Subconjunctival Bevacizumab
Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF) to inhibit abnormal blood vessel formation in the eye.
Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor (VEGF) to inhibit abnormal blood vessel formation in the eye. Used for Neovascular age-related macular degeneration, Diabetic macular edema, Retinal vein occlusion with macular edema.
At a glance
| Generic name | Subconjunctival Bevacizumab |
|---|---|
| Sponsor | Grewal Eye Institute |
| Drug class | VEGF inhibitor (monoclonal antibody) |
| Target | VEGF (Vascular Endothelial Growth Factor) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
When administered subconjunctivally (injected under the conjunctiva), bevacizumab binds to and neutralizes VEGF, a key driver of pathological neovascularization. This reduces abnormal vessel growth and associated complications in retinal and choroidal diseases. The subconjunctival route provides local ocular delivery while minimizing systemic exposure.
Approved indications
- Neovascular age-related macular degeneration
- Diabetic macular edema
- Retinal vein occlusion with macular edema
- Corneal neovascularization
Common side effects
- Conjunctival injection/hyperemia
- Subconjunctival hemorrhage
- Eye pain or discomfort
- Anterior chamber inflammation
Key clinical trials
- Assessing Combined Bevacizumab-Mitomycin C Use During Ahmed Valve Revision in Recurrent Pediatric Glaucoma (EARLY_PHASE1)
- Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization (PHASE2, PHASE3)
- Preoperative Bevacizumab Injection in Primary Pterygium in Tunisian Patients (PHASE4)
- Pain Control and Subconjunctival Hemorrhage Size After Intravitreal Injection (NA)
- The Use of Bevacizumab as a Modulator of Wound Healing Following Trabeculectomy Surgery (PHASE3)
- Outpatient Performed Pterygium Surgery Study (PHASE4)
- A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival (PHASE1, PHASE2)
- Efficacy and Safety Study of Avastin to Treat Neovascularisation of the Cornea (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Subconjunctival Bevacizumab CI brief — competitive landscape report
- Subconjunctival Bevacizumab updates RSS · CI watch RSS
- Grewal Eye Institute portfolio CI